Navigation Links
Gene-Eden-VIR Has Best Value; polyDNA Compares Treatments for HPV Infection
Date:4/29/2013

Rochester, NY (PRWEB) April 29, 2013

polyDNA recommends Gene-Eden-VIR as the most cost effective means of treating a latent HPV infection. During Money Smart Week (1), polyDNA is doing its part by contrasting the cost of HPV treatments. One of those treatments is Gene-Eden-VIR, a natural remedy against the latent HPV virus.

This week, the media, government agencies, not-for-profits, schools, financial institutions and businesses of all kinds are working together to help customers manage their personal finances better. To help customers who suffer from HPV infections, polyDNA compared the cost of Gardasil, Cervarix and Gene-Eden-VIR. The first two are FDA approved vaccines while the third is a natural, antiviral remedy.

“All my friends have been getting the HPV jab. But, I’ve been waiting it out. I’ve read some stuff online about the studies done on them, Gardasil for sure, only lasts for like…5 years. Then you know, it only protects against 4 strains and I read that there are more than 40 types that can infect the genitals, so for $390, it sounds like Gardasil’s protection is super limited.” -Irene D.

The only FDA drugs approved for HPV prevention are Gardasil and Cervarix. Both are vaccines. Gardasil protects against four HPV strains, and Cervarix protects against two. Neither vaccine is effective if someone is already infected with one of these HPV strains. (2)(3)

According to Cancer.org, the cost of Gardasil is $130 per dose, and it requires at least 3 doses for a person to be considered fully vaccinated. This means that the full cost of vaccination with Gardasil is $390.00. (4)

In 2011 the cost of Cervarix was lowered from $134.95 to $90.00 per dose. (5) However, even at $90.00 per dose, (again at 3 doses for full vaccination) Cervarix comes to a total of $270.00. That’s $120.00 less than Gardasil, but for some customers this cost is still significant.

Gene-Eden-VIR is an ant
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Gene-Eden-VIR is Most Cost Effective; polyDNA Compares Treatments for Herpes Infection
2. GYT and Take Gene-Eden-VIR; polyDNA Recommends an HPV Remedy to Infected Individuals
3. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
4. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
5. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
6. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
7. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
8. Lung Cancer Survivors Share Stories of Value of Early Detection and Hope for More Effective Treatments
9. Only 16% of Donations go to New Cancer Treatments in Some Charities. With cureLauncher, 91% of Contributions Go Directly to New Cures for Cancer.
10. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
11. Bacterias hidden skill could pave way for stem cell treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 A new ... it easier for research institutions to learn how Apple’s ... data. , The timing is ideal since Apple made ... Research Kit is an open-source framework for developing medical ... provides a way for researchers to collect secure clinical ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, today ... has been added as a clinical trial site for ... patients with refractory glioblastoma multiforme (GBM), the most common ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... GNVC ) today announced its financial results for the third ... $3.6 million ($0.04 per share) for the three months ended September ... per share) in the comparable quarter of 2008. For the nine ... ($0.15 per share), compared to a net loss of $19.6 million ...
... Conference Call on Thursday, November 5, 2009 at 4:30 ... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the ... results for the third quarter and nine months ended ... the third quarter of 2009. , The following consolidated ...
... DIEGO, CA, November 5, 2009 Senomyx, Inc. (Nasdaq: ... technologies to discover novel flavor ingredients for the food, beverage, ... reported financial results for the third quarter ended September 30, ... of 2009, compared to $4.0 million for the third quarter ...
Cached Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Earth,s history has been going on for hundreds of millions of ... existed, scientists reported today in the journal Nature . ... organism in the oceans, survives where most other cells would die ... had been theorized that SAR11 was so small and widespread that ...
... University of Alberta study shows that busy beavers are helping Canada ... begin spring nesting. Ponds in Alberta where beavers were active ... geese a better chance at reproductive success, according to the study, ... the first to link beavers to early season nesting habits of ...
... the NSERC Canadian Network for Aquatic Ecosystems (CNAES) will ... made when it comes to this country,s wetlands, lakes ... from the Natural Sciences and Engineering Research Council, in ... organizations, was recently announced as part of the government,s ...
Cached Biology News:A war without end -- with Earth's carbon cycle held in the balance 2Canada's aquatic ecosystems research gets boost from NSERC 2
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
...
Biology Products: